Merus BV, a Dutch developer of bispecific antibodies for cancer immunotherapy, claimed the first tranche of a €72.8 million (US$80.5 million) series financing led by Sofinnova Ventures and Novo A/S, with additional backing from RA Capital Healthcare Fund, Rock Springs Capital, Tekla Capital Management, an unnamed U.S. investor and earlier supporters.